ACTN2

ACTN2 encodes alpha-actinin-2, a Z-disc structural protein essential for sarcomere assembly and contractile function in cardiac and skeletal muscle (PMID:27287556, PMID:30701273). Its calponin-homology actin-binding domain directly engages F-actin, and HCM-associated mutations in this domain perturb its structure, reduce F-actin binding affinity, and impair Z-disc localization and dynamics in cardiomyocytes (PMID:27287556). The protein's incorporation into the sarcomere is gated by the cell cycle: CDK1 phosphorylates ACTN2 at Thr308, and phospho-null cells assemble robust sarcomeres while phosphomimetic cells fail, coupling cell-cycle exit to sarcomere maturation (PMID:41953953). A recurrent disease theme is proteostatic failure — pathogenic missense and protein-extending frameshift variants destabilize or aggregate alpha-actinin-2, activating the ubiquitin-proteasome system and autophagy-lysosomal pathway and producing myofibrillar disarray, force impairment, and in mice embryonic lethality with mitochondrial and cell-cycle defects (PMID:36078153, PMID:36899856, PMID:39095936, PMID:38293186). Beyond its structural role, loss of ACTN2 in stressed cardiomyocytes promotes hypertrophy through excessive MAPK/ERK activation (PMID:38990270), and its expression is transcriptionally controlled by XBP1 under ER stress and by PRDM9 via H3K4me3 (PMID:32451822, PMID:40881324). Dominant missense mutations in ACTN2 cause adult-onset distal myopathy (actininopathy), extending its disease spectrum beyond cardiac muscle (PMID:30900782).

1. 2016 High

   Established at structural and biochemical resolution how disease mutations in the actin-binding domain impair ACTN2's core function — linking F-actin engagement to Z-disc integration.

   Evidence X-ray crystallography and circular dichroism of purified ABD with F-actin co-sedimentation and live-cell imaging of tagged full-length protein in adult cardiomyocytes

   PMID:27287556

   Open questions at the time

   • Did not establish how reduced F-actin affinity propagates to contractile force in intact tissue
   • Only two HCM mutations examined
2. 2019 High

   Demonstrated that ACTN2 mutations cause skeletal muscle disease in vivo, showing mutant protein localizes correctly yet still disorganizes the sarcomere and impairs force — a dominant-negative structural effect rather than simple mislocalization.

   Evidence Exome sequencing, zebrafish and AAV-mouse expression of mutant vs. wild-type ACTN2, isolated muscle force measurement, myotube immunofluorescence

   PMID:30701273

   Open questions at the time

   • Molecular basis of disorganization despite correct Z-line targeting unresolved
   • Did not define proteostatic consequences
3. 2019 Low

   Defined ACTN2 as a skeletal-muscle disease gene through dominant missense mutations causing adult-onset distal myopathy, broadening its phenotype beyond cardiac roles.

   Evidence Whole-exome sequencing and co-segregation in 4 families with muscle biopsy histopathology

   PMID:30900782

   Open questions at the time

   • No in vitro or in vivo functional assay of mutant protein in this study
   • Mechanism connecting genotype to histopathology not established
4. 2020 Medium

   Identified transcriptional control of ACTN2 under ER stress, showing XBP1 sustains alpha-actinin-2 levels while related ACTN3 is downregulated, distinguishing isoform-specific UPR regulation.

   Evidence Promoter reporter assays with UPR transcription factor overexpression, RT-qPCR and Western blotting in C2C12 myotubes under ER stress

   PMID:32451822

   Open questions at the time

   • Direct XBP1 binding to the ACTN2 promoter not mapped
   • Physiological relevance in muscle tissue untested
5. 2022 High

   Defined proteopathy as a disease mechanism — showing a pathogenic missense variant aggregates and triggers proteostatic clearance pathways with functional force loss in human cardiac tissue.

   Evidence Isogenic CRISPR knock-in hiPSC-CM lines with proteomics, live imaging, RNA-seq, and engineered heart tissue contractility

   PMID:36078153

   Open questions at the time

   • Whether aggregation is cause or consequence of force loss not fully separated
   • Single variant studied
6. 2023 High

   Extended the destabilization/proteostasis model in vivo, linking a destabilizing variant to UPS activation, cell-cycle and mitochondrial defects, and embryonic lethality.

   Evidence Knock-in mouse model with echocardiography, episcopic microscopy, unbiased proteomics, qPCR and Western blotting

   PMID:36899856

   Open questions at the time

   • Causal hierarchy between sarcomeric, cell-cycle and mitochondrial phenotypes unresolved
   • Mechanism connecting alpha-actinin-2 loss to mitochondrial dysfunction unknown
7. 2024 Medium

   Distinguished variant-class-specific pathomechanisms, showing protein-extending frameshift variants aggregate whereas recessive missense variants do not — tying aggregation specifically to dominant frameshift actininopathy.

   Evidence C2C12 cell expression of frameshift vs. missense variants with immunofluorescence aggregate detection

   PMID:38293186 PMID:39095936

   Open questions at the time

   • Single method (immunofluorescence) without biochemical aggregate characterization
   • Effect on contractile function not measured
8. 2024 Medium

   Revealed a signaling role beyond structure: ACTN2 loss under stress drives hypertrophy via MAPK/ERK, with pharmacological ERK inhibition partially rescuing.

   Evidence siRNA knockdown in H9c2 cells with transcriptomics, Western blot for ERK phosphorylation, and ERK inhibitor rescue

   PMID:38990270

   Open questions at the time

   • Mechanism linking alpha-actinin-2 to ERK activation undefined
   • Single cell line and stress context
9. 2024 Medium

   Identified ACTN4 as a heterodimeric partner of ACTN2 at the cardiac Z-disc whose level tunes sarcomere stability and contractility-dependent hypertrophy.

   Evidence Co-immunoprecipitation, AI structural modeling, siRNA depletion in hiPSC-CMs, contractility, and zebrafish loss-of-function (preprint)

   PMID:bio_10.1101_2024.11.26.625523

   Open questions at the time

   • Preprint, not peer-reviewed
   • Stoichiometry and structural basis of heterodimer not biochemically resolved
10. 2025 Medium

    Connected ACTN2 to epigenetic regulation and Hippo signaling, with PRDM9 driving its transcription and PDLIM1 interaction mediating vascular smooth muscle function.

    Evidence ChIP-qPCR, CRISPR PRDM9 editing, co-IP for PDLIM1, and functional rescue in VSMCs

    PMID:40881324

    Open questions at the time

    • Role of ACTN2 in non-muscle VSMC context not independently confirmed
    • PDLIM1 interaction not reciprocally validated
11. 2025 Medium

    Placed ACTN2 within a dosage-sensitive maturation feedback loop, where RBFOX2-dependent ACTN2 levels feed back through mechanosensing to drive cardiomyocyte transcriptome maturation.

    Evidence RBFOX2 heterozygous and null hiPSC-CM models with ACTN2 overexpression rescue, contractility, RNA-seq and mechanosensing assays (preprint)

    PMID:bio_10.1101_2025.10.28.685214

    Open questions at the time

    • Preprint, not peer-reviewed
    • Molecular components of the mechanosensing feedback not defined
12. 2026 High

    Established post-translational coupling of cell-cycle exit to sarcomere assembly via CDK1 phosphorylation of ACTN2 at Thr308.

    Evidence In vitro CDK1 kinase assay with mutagenesis and CRISPR knock-in of T308A/T308D in C2C12 cells with sarcomere imaging and proliferation assays

    PMID:41953953

    Open questions at the time

    • How phosphorylation alters ACTN2 binding or localization mechanistically unresolved
    • In vivo relevance in developing heart untested

• How the distinct disease mechanisms (impaired actin binding, protein aggregation/proteostatic failure, and altered signaling) are integrated, and what determines the cardiac versus skeletal phenotype of a given variant, remains unresolved.
• No unified model linking variant class to tissue-specific outcome
• Structural basis of Thr308 phosphoregulation undefined
• Mechanism of ACTN2-dependent ERK and Hippo signaling unknown